Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes
Status:
Recruiting
Trial end date:
2026-06-15
Target enrollment:
Participant gender:
Summary
The aim of this clinical trial is to evaluate if colchicine in addition to standard of care
improves markers of inflammation and cardiovascular disease in persons with type 1 diabetes.
Participants will be assigned to either 0,5 mg colchicine daily or placebo in a 1:1 ratio for
26 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Filip Krag Knop
Collaborators:
Juvenile Diabetes Research Foundation University of Copenhagen